Alliance Pharma plc (LON:APH - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as GBX 61.50 ($0.76) and last traded at GBX 61.20 ($0.75), with a volume of 8782805 shares. The stock had previously closed at GBX 61.10 ($0.75).
Alliance Pharma Price Performance
The company has a debt-to-equity ratio of 47.46, a current ratio of 2.93 and a quick ratio of 1.42. The firm has a market capitalization of £330.83 million, a price-to-earnings ratio of -1,020.00, a PEG ratio of 1.04 and a beta of 0.67. The business's fifty day simple moving average is GBX 48.48 and its 200 day simple moving average is GBX 43.21.
About Alliance Pharma
(
Get Free Report)
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alliance Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alliance Pharma wasn't on the list.
While Alliance Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
